Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor.
Passoni P, Fiorino C, Slim N, Ronzoni M, Ricci V, Di Palo S, De Nardi P, Orsenigo E, Tamburini A, De Cobelli F, Losio C, Iacovelli NA, Broggi S, Staudacher C, Calandrino R, Di Muzio N. Passoni P, et al. Among authors: ronzoni m. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):67-72. doi: 10.1016/j.ijrobp.2013.05.004. Epub 2013 Jun 19. Int J Radiat Oncol Biol Phys. 2013. PMID: 23790770
Complications after percutaneous transaxillary implantation of a catheter for intraarterial chemotherapy of liver tumors: clinical relevance and management in 204 patients.
Venturini M, Angeli E, Salvioni M, De Cobelli F, Ronzoni M, Aldrighetti L, Stella M, Carlucci M, Staudacher C, Di Carlo V, Ferla G, Villa E, Del Maschio A. Venturini M, et al. Among authors: ronzoni m. AJR Am J Roentgenol. 2004 Jun;182(6):1417-26. doi: 10.2214/ajr.182.6.1821417. AJR Am J Roentgenol. 2004. PMID: 15149985
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Ruzzo A, et al. Among authors: ronzoni m. Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828. Sci Rep. 2014. PMID: 25370899 Free PMC article. Clinical Trial.
Aflibercept a new target therapy in cancer treatment: a review.
Ricci V, Ronzoni M, Fabozzi T. Ricci V, et al. Among authors: ronzoni m. Crit Rev Oncol Hematol. 2015 Dec;96(3):569-76. doi: 10.1016/j.critrevonc.2015.07.001. Epub 2015 Jul 8. Crit Rev Oncol Hematol. 2015. PMID: 26224565 Review.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. Cremolini C, et al. Among authors: ronzoni m. Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31. Lancet Oncol. 2015. PMID: 26338525 Clinical Trial.
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest. Cremolini C, et al. Among authors: ronzoni m. BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z. BMC Cancer. 2017. PMID: 28599628 Free PMC article. Clinical Trial.
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R; TOSCA Investigators. Sobrero A, et al. Among authors: ronzoni m. J Clin Oncol. 2018 May 20;36(15):1478-1485. doi: 10.1200/JCO.2017.76.2187. Epub 2018 Apr 5. J Clin Oncol. 2018. PMID: 29620994 Clinical Trial.
A TCP-based early regression index predicts the pathological response in neo-adjuvant radio-chemotherapy of rectal cancer.
Fiorino C, Gumina C, Passoni P, Palmisano A, Broggi S, Cattaneo GM, Di Chiara A, Esposito A, Mori M, Raso R, Ronzoni M, Rosati R, Slim N, De Cobelli F, Calandrino R, Di Muzio NG. Fiorino C, et al. Among authors: ronzoni m. Radiother Oncol. 2018 Sep;128(3):564-568. doi: 10.1016/j.radonc.2018.06.019. Epub 2018 Jun 29. Radiother Oncol. 2018. PMID: 30196982
95 results